Black Hawk Acquisition (BKHA) vs Eloxx Pharmaceuticals (ELOX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $51.2 million), about 1.2 times the size. On valuation, Eloxx Pharmaceuticals trades at a lower trailing P/E (4.3x vs 37.4x for Black Hawk Acquisition).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | ELOX |
|---|---|---|
| Share price | $12.33 | $15.18 |
| Market cap | $51.21M | $61.27M |
| 1-day change | -5.15% | +2.02% |
| P/E ratio (TTM) | 37.36 | 4.31 |
| EPS (TTM) | $0.33 | $3.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $23.40 |
| 52-week low | $11.00 | $8.20 |
| Distance from 52-week high | -6.24% | -35.13% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +151.98% |
| Average volume | 5.83K | 44.52K |
| Shares outstanding | 4.15M | 4.04M |
| Employees | — | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Black Hawk Acquisition trades at a higher earnings multiple (37.4x vs 4.3x trailing P/E).
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
BKHA vs ELOX FAQ
Which is bigger, Black Hawk Acquisition or Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $51.21M for Black Hawk Acquisition (BKHA).
Which has the lower P/E ratio, BKHA or ELOX?
ELOX has the lower trailing P/E at 4.3, versus 37.4 for BKHA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Black Hawk Acquisition and Eloxx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.